May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
August 2018 in “Dermatologic Surgery” 36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
October 2022 in “Zenodo (CERN European Organization for Nuclear Research)” EndoPump Male Enhancement lacks proven effectiveness and may pose health risks.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
37 citations
,
May 2003 in “Journal of Consumer Marketing” The debate on direct-to-consumer pharmaceutical ads continues, with consumers finding them educational and doctors concerned about their impact on patient relationships and medication understanding.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
July 2016 in “Dermatologie pro praxi” Espumil foam base allows easy preparation of skin medications for hairy areas.
14 citations
,
April 2002 in “Brain Research Protocols” Quickly get finasteride from tablets using easy methods.
1 citations
,
October 2021 in “Indian Journal of Plastic Surgery” Hair transplant surgery in India has progressed from plugs and flaps to advanced techniques using micrografts and follicular unit extraction.
January 2019 in “Analytical Science and Technology” About 21% of tested hair loss supplements contained illegal synthetic drugs.
5 citations
,
February 2021 in “Journal of The American Academy of Dermatology” Online skin care companies offer easy access to treatments but may have ethical issues like confirming patient identity, prescribing unproven therapies, and not fully explaining medication side effects. They should prioritize patient care over profit.
June 2022 in “C&EN global enterprise” The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
2 citations
,
July 2025 in “Discover Chemistry.” Alstonia boonei phytochemicals show promise as alternative treatments for BPH with fewer side effects than current drugs.
6 citations
,
February 2016 in “Journal of Microencapsulation” Improved finasteride formula allows slow, sustained release and better absorption for patients.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
64 citations
,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
1 citations
,
January 1979 in “International Journal of Dermatology” Cyproterone acetate effectively treats hirsutism and related conditions.
January 2023 in “IntechOpen eBooks” The document concludes that specific methods for making diazine-based drugs can lead to high yields and are important for creating effective treatments for various diseases.
July 2010 in “Hair transplant forum international” The ABHRS held a test in Capri, Italy.
Self-assembling peptide hydrogels effectively deliver drugs locally, enhancing treatment and reducing side effects.
January 1982 in “Clin-Alert” Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
May 1981 in “Inpharma (Balgowlah)” Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.